Scientists Test 10,000 Molecules to Find the Next Longevity Breakthrough
Dr. Benjamin Blue reveals how his company screens thousands of compounds for lifespan extension using AI and robotics.
Summary
Dr. Benjamin Blue, CEO of Ora Biomedical, discusses his company's systematic approach to discovering longevity molecules using high-throughput screening in roundworms. His team has tested nearly 10,000 compounds, finding that 3% extend lifespan by 30% or more, with the best achieving 60-70% extension. Notable successes include novel mTOR inhibitors and supplements like sulforaphane (40% extension) and taurine. Disappointments included rapamycin (due to dosing issues), curcumin, and quercetin. The company aims for their "Million Molecule Challenge" to find compounds extending lifespan by 100-200% through combination therapies. Beyond longevity, they're developing radiation-protective therapies for cancer patients and astronauts, leveraging the connection between aging and DNA damage repair.
Detailed Summary
This interview reveals a systematic, data-driven approach to longevity research that could accelerate the discovery of life-extending compounds. Dr. Benjamin Blue's company uses AI-powered robotics to rapidly screen thousands of molecules in roundworms, which live only three weeks, allowing quick assessment of lifespan effects before moving to human cell studies and eventually mouse trials.
The screening results offer both validation and surprises for the longevity community. While some popular supplements like sulforaphane and taurine showed significant effects (up to 40% lifespan extension), others like curcumin, quercetin, and even rapamycin disappointed. Novel mTOR inhibitors emerged as the most promising category, with some achieving 60-70% lifespan extension - approaching the 100% seen in genetic modifications.
The company's "Million Molecule Challenge" represents an ambitious scaling effort, moving from testing hundreds of known compounds to exploring vast chemical libraries of natural products and synthetic molecules. With a 3% hit rate for meaningful lifespan extension, this approach could yield thousands of promising candidates. The ultimate goal involves combination therapies that could achieve 200-300% lifespan extension.
Practically, the research is already yielding near-term applications. The team discovered that their best longevity compounds also protect against radiation damage, leading to partnerships with the Air Force and potential treatments for cancer patients undergoing radiation therapy. This connection between aging and DNA repair mechanisms suggests these compounds could reduce skin cancer risk and improve recovery from radiation exposure, providing immediate health benefits while longer-term longevity research continues.
Key Findings
- Novel mTOR inhibitors achieved 60-70% lifespan extension in roundworms, outperforming rapamycin
- Sulforaphane extended lifespan by up to 40%, while curcumin and quercetin showed minimal effects
- 3% of screened molecules extend lifespan by 30%+ with systematic high-throughput testing
- Longevity compounds also protect against radiation damage, offering near-term clinical applications
- Combination therapies may achieve 200-300% lifespan extension beyond single-molecule limits
Methodology
This is an interview-format video from Siim Land's longevity-focused YouTube channel featuring Dr. Benjamin Blue, CEO of Ora Biomedical. The discussion covers both published research and ongoing proprietary studies from the company's systematic screening platform.
Study Limitations
Results are primarily from roundworm studies, which may not translate directly to humans. Some promising compounds remain proprietary and undisclosed. The interview format doesn't provide detailed methodology or statistical analysis, and human clinical trial data is not yet available for the novel compounds discussed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.